Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Docetaxel + Ramucirumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Docetaxel||Taxotere||RP56976||Antimicrotubule Agent 12||Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558).|
|Ramucirumab||Cyramza||LY3009806||VEGFR2 Antibody 4||Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is FDA approved for use as a monotherapy or in combination with paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma who progressed on chemotherapy, in combination with erlotinib as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations or L858R, in combination with decetaxel in patients with NSCLC who progressed on prior therapy, in combination with FOLFIRI in patients with colorectal cancer who progressed on prior therapy, and as monotherapy in patients with hepatocellular carcinoma who have received sorafenib (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Docetaxel + Ramucirumab||FDA approved||Actionable||In a Phase III trial (REVEL) that supported FDA approval, Cyramza (ramucirumab) and Taxotere (docetaxel) combination treatment resulted in improved overall survival (10.5 vs 9.1 mo, HR=0.86, p=0.023) compared to Taxotere (docetaxel) and a placebo in patients with metastatic non-small cell lung cancer whose disease progressed on prior chemotherapy (PMID: 24933332; NCT01168973).||24933332 detail...|
|Unknown unknown||transitional cell carcinoma||not applicable||Docetaxel + Ramucirumab||Phase II||Actionable||In a Phase II trial, Cyramza (ramucirumab) and Taxotere (docetaxel) combination treatment resulted in improved median progression-free survival (5.4 months) when compared to Taxotere (docetaxel) single treatment (2.8 months) in urothelial carcinoma patients (PMID: 26926681).||26926681|
|Unknown unknown||transitional cell carcinoma||not applicable||Docetaxel + Ramucirumab||Phase III||Actionable||In a Phase III trial, Cyramza (ramucirumab) and Taxotere (docetaxel) combination treatment resulted in improved median progression-free survival (4.1 vs 2.8 months) and objective response rate (24.5% vs 14.0%) when compared to Taxotere (docetaxel) single treatment in urothelial carcinoma patients (Annals of Oncology (2017) 28 (suppl_5): v605-v649; NCT02426125).||detail...|
|ERBB2 negative||Her2-receptor negative breast cancer||no benefit||Docetaxel + Ramucirumab||Phase III||Actionable||In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099).||25185099|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02831491||Phase II||Docetaxel + Ramucirumab||A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer||Withdrawn|
|NCT04310007||Phase II||Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab||Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer||Recruiting|
|NCT03971474||Phase II||Docetaxel + Gemcitabine + Pemetrexed Disodium Docetaxel + Ramucirumab Docetaxel + Gemcitabine Pembrolizumab + Ramucirumab||Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)||Recruiting|